Equinix Newsroom

While COVID-19 has affected all industries, the impact on the healthcare and life sciences industry has been twofold. On one hand, the industry faced similar challenges as the others; organizations had to relook at how they serve their patients and customers as well as how they collaborate within departments and with their partners. On the other hand, they were in a race against time to find a solution for this global crisis — and arguably one of the greatest challenges that humanity is facing in history.

According to a report by Evaluate Pharma in 2020, pharmaceutical companies spend, on average, 17% of revenues on R&D, making it one of the biggest spenders in this area.[i]

These R&D advancements have led to a surge in data exchanges and IDC has noted that the amount of data created over the next three years will be more than the data created over the past 30 years. The increase in data exchanges and collaboration calls for more secure private connections between healthcare and life sciences organizations. In the recently released Global Interconnection Index (GXI) Vol.4, a market study by Equinix, it is predicted that the interconnection bandwidth, i.e. private data exchange, for Healthcare and Life Sciences in Asia-Pacific is expected to grow at 47% CAGR by 2023.